01 October 2021>: Original Paper
Outcomes After Living Donor Liver Transplantation in Pediatric Patients with Inherited Metabolic Diseases
Yukihiro Sanada ABCDEF* , Yasunaru Sakuma DF , Yasuharu Onishi B , Noriki Okada B , Naoya Yamada B , Yuta Hirata B , Go Miyahara B , Takumi Katano B , Toshio Horiuchi B , Takahiko Omameuda B , Alan Kawarai Lefor DF , Naohiro Sata DFDOI: 10.12659/AOT.932994
Ann Transplant 2021; 26:e932994
Table 2 Univariate analysis of risk factors for post-transplant complications in recipients with IMDs and BA.
Variable | Recipients with IMDsN=44 | Recipients with BAN=221 | p-value |
---|---|---|---|
Hepatic vein complications | 2 (4.5%) | 15 (6.8%) | 0.746 |
Portal vein complications | 4 (9.1%) | 38 (17.2%) | 0.257 |
Hepatic artery complications | 2 (4.5%) | 11 (5.0%) | 0.999 |
Biliary complications | 8 (18.2%) | 45 (20.4%) | 0.839 |
Re-laparotomy after LDLT | 7 (15.9%) | 22 (10.0%) | 0.288 |
Acute cellular rejection | 12 (27.3%) | 98 (44.3%) | 0.044 |
Steroid-resistant acute rejection | 1 (2.3%) | 26 (11.8%) | 0.059 |
Cytomegalovirus viremia | 22 (50.0%) | 73 (33.0%) | 0.039 |
Post-transplant lymphoproliferative disorder | 0 (0%) | 6 (2.7%) | 0.594 |
Hospital length of stay | 62±107 days | 43±30 days | 0.125 |
IMDs – inherited metabolic diseases; BA – biliary atresia; LDLT – living donor liver transplantation. |